| Schedule of financial information by reportable segment |
The following is financial information relating to the operating segments (in thousands):
|
|
|
|
|
|
|
|
|
For the Year Ended June 30, 2025 |
|
|
Protein Sciences |
|
|
Diagnostics and Spatial Biology |
|
|
Total |
Net sales |
$ |
870,245 |
|
$ |
346,263 |
|
$ |
1,216,508 |
Other revenue(1) |
|
|
|
|
|
|
|
4,152 |
Intersegment |
|
|
|
|
|
|
|
(1,025) |
Consolidated net sales |
|
|
|
|
|
|
$ |
1,219,635 |
Segment operating income |
|
|
|
|
|
|
|
|
Cost of sales |
|
212,225 |
|
|
147,946 |
|
|
|
Selling, general and administrative |
|
229,058 |
|
|
136,103 |
|
|
|
Research and development |
|
58,609 |
|
|
40,890 |
|
|
|
Segment operating income |
$ |
370,353 |
|
$ |
21,324 |
|
$ |
391,677 |
Unallocated amounts |
|
|
|
|
|
|
|
|
Costs recognized on sale of acquired inventory |
|
|
|
|
|
|
|
(751) |
Amortization of intangibles |
|
|
|
|
|
|
|
(75,321) |
Acquisition related expenses and other |
|
|
|
|
|
|
|
(12,064) |
Certain litigation charges |
|
|
|
|
|
|
|
(41,827) |
Impairment of assets held-for-sale |
|
|
|
|
|
|
|
(80,503) |
Stock based compensation, inclusive of employer taxes |
|
|
|
|
|
|
|
(42,158) |
Restructuring and restructuring-related costs |
|
|
|
|
|
|
|
(28,231) |
Corporate general, selling, and administrative expenses |
|
|
|
|
|
|
|
(8,088) |
Impact of business held-for-sale(1) |
|
|
|
|
|
|
|
(479) |
Consolidated operating income |
|
|
|
|
|
|
$ |
102,255 |
| (1) |
Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. Segment results exclude the results of this business held-for-sale for fiscal 2025. |
|
|
|
|
|
|
|
|
|
For the Year Ended June 30, 2024 |
|
|
Protein Sciences |
|
|
Diagnostics and Spatial Biology |
|
|
Total |
Net sales |
$ |
830,902 |
|
$ |
326,392 |
|
$ |
1,157,294 |
Other revenue(1) |
|
|
|
|
|
|
|
4,153 |
Intersegment |
|
|
|
|
|
|
|
(2,387) |
Consolidated net sales |
|
|
|
|
|
|
$ |
1,159,060 |
Segment operating income |
|
|
|
|
|
|
|
|
Cost of sales |
|
201,981 |
|
|
134,963 |
|
|
|
Selling, general and administrative |
|
217,235 |
|
|
127,131 |
|
|
|
Research and development |
|
56,911 |
|
|
39,752 |
|
|
|
Segment operating income |
$ |
354,775 |
|
$ |
24,546 |
|
$ |
379,321 |
Unallocated amounts |
|
|
|
|
|
|
|
|
Costs recognized on sale of acquired inventory |
|
|
|
|
|
|
|
(729) |
Amortization of intangibles |
|
|
|
|
|
|
|
(78,318) |
Acquisition related expenses and other |
|
|
|
|
|
|
|
(6,980) |
Certain litigation charges |
|
|
|
|
|
|
|
(3,506) |
Impairment of assets held-for-sale |
|
|
|
|
|
|
|
(21,963) |
Stock based compensation, inclusive of employer taxes |
|
|
|
|
|
|
|
(40,277) |
Restructuring and restructuring-related costs |
|
|
|
|
|
|
|
(12,245) |
Corporate general, selling, and administrative expenses |
|
|
|
|
|
|
|
(9,142) |
Impact of business held-for-sale(1) |
|
|
|
|
|
|
|
525 |
Consolidated operating income |
|
|
|
|
|
|
$ |
206,686 |
| (1) |
Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. Segment results exclude the six-month results of this business held-for-sale for the period starting December 31, 2023 through June 30, 2024 while the business has met the held-for-sale criteria. |
|
|
|
|
|
|
|
|
|
For the Year Ended June 30, 2023 |
|
|
Protein Sciences |
|
|
Diagnostics and Spatial Biology |
|
|
Total |
Net sales |
$ |
845,747 |
|
$ |
292,602 |
|
$ |
1,138,349 |
Intersegment |
|
|
|
|
|
|
|
(1,647) |
Consolidated net sales |
|
|
|
|
|
|
$ |
1,136,702 |
Segment operating income |
|
|
|
|
|
|
|
|
Cost of sales |
|
209,332 |
|
|
113,517 |
|
|
|
Selling, general and administrative |
|
204,480 |
|
|
101,806 |
|
|
|
Research and development |
|
58,251 |
|
|
34,242 |
|
|
|
Segment operating income |
$ |
373,684 |
|
$ |
43,037 |
|
$ |
416,721 |
Unallocated amounts |
|
|
|
|
|
|
|
|
Costs recognized on sale of acquired inventory |
|
|
|
|
|
|
|
(400) |
Amortization of intangibles |
|
|
|
|
|
|
|
(76,413) |
Impact of partially-owned consolidated subsidiaries |
|
|
|
|
|
|
|
647 |
Acquisition related expenses and other |
|
|
|
|
|
|
|
9,965 |
Stock based compensation, inclusive of employer taxes |
|
|
|
|
|
|
|
(41,217) |
Restructuring and restructuring-related costs |
|
|
|
|
|
|
|
(3,829) |
Corporate general, selling, and administrative expenses |
|
|
|
|
|
|
|
(6,530) |
Consolidated operating income |
|
|
|
|
|
|
$ |
298,944 |
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended June 30, |
|
|
2025 |
|
2024 |
|
2023 |
Consumables revenue - Protein Sciences |
|
$ |
684,165 |
|
$ |
657,679 |
|
$ |
665,301 |
Consumables revenue - Diagnostics and Spatial Biology |
|
|
283,969 |
|
|
266,348 |
|
|
252,432 |
Consumables revenue - Other revenue(1) |
|
|
4,152 |
|
|
4,153 |
|
|
— |
Total consumable revenue |
|
$ |
972,286 |
|
$ |
928,180 |
|
$ |
917,733 |
| (1) |
Includes the results of a business that has met the held-for-sale criteria since December 31, 2023. |
|